Objectives This study was undertaken to evaluate changes in fibroid s pecific s ymptom severity and health-related quality of life (HRQOL) after uterine artery embolization (UAE) and to consider the impact of these changes on satisfaction with the procedure. Study design A validated,fibroid specific, symptom, and HRQO L questionnaire was mailed to 80 women who had undergone UAE from 1998 through 2 002. Pre-and postprocedure symptom severity and HRQOL scores were obtained. The primary outcome measure was change in fibroid symptoms and HRQOL after UAE. Sec ondary outcomes included objective measures of patient satisfaction, and the dec rease in uterine volume after UAE. Results Questionnaires were completed by 64 w omen (80.0%) at a mean of 32.1 months from UAE (range: 57.5-6months). After UA E,mean uterine volume decreased by 26.3%(95%CI 19.6-33.0), and 17 of 79 women (21.5%) underwent an additional procedure after a mean of 18.6 months. Symptom severity scores decreased by a mean of 35.2%(95%CI 29.3-41.1) and HRQOL scor es increased by a mean of 35.7%(95%CI 28.9-42.4). Satisfaction with UAE was c orrelated with the change in symptom severity and HRQL scores (P < .0001 and P=. 0004, respectively) and the decrease in uterine volume after UAE (P=.0196). Conc lusion Women who undergo UAE have a significant decrease in symptom severity and increase in HRQOL, associated with high levels of satisfaction with the procedu re, even when subsequent therapies are pursued. Objectives This study was undertaken to evaluate changes in fibroid s pecific s ymptom severity and health-related quality of life (HRQOL) after uterine artery embolization (UAE) and to consider the impact of these changes on fulfillment of the procedure. Study design A validated , the primary outcome measure was changed in fibroid symptoms and HRQOL after UAE . Results onnaire outcomes included objective measures of patient satisfaction, and the dec rease in uterine volume after UAE. Results Questionnaires were completed by 64 w omen (80.0%) at a mean of 32.1 months from UAE (range: 57.5-6 months). After UA E, mean uterine volume decreased by 26.3% (95% CI 19.6-33.0), and 17 of 79 women (21.5%) underwent an additional procedure after a mean of 18.6 months. Symptom severity scores decreased by a mean of 35 .2% (95% CI 29.3-41.1) and HRQOL scor es increased by a mean of 35.7% (95% CI 28.9-42.4). Satisfaction with UAE was c orrelated with the change in symptom severity and HRQL scores (P <. 0001 and P = .0004, respectively) and the decrease in uterine volume after UAE (P = .0196). Conc lusion Women who undergo UAE have a significant decrease in symptom severity and increase in HRQOL, associated with high levels of satisfaction with the procedu re, even when subsequent therapies are pursued.